Idelasinib blocks one form of PI3K (delta), whereas duvelisib blocks two forms (delta and gamma). Because of new research into the potential safety risks of PI3K inhibitors, these therapies are ...

Pharming has submitted its oral phosphoinositide 3-kinase delta (PI3Kδ) inhibitor leniolisib for approval in the EU as a treatment for activated PI3K delta syndrome (APDS), an ultra-rare disease ...

Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its ...